Infensa Bioscience
PrivateLast Round
Grant
Oct 7, 2024
Total Funding Raised
$27.66M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Infensa Bioscience is a biotechnology company that develops peptide-based therapeutic candidates to reduce mortality and morbidity associated with heart attacks and strokes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Infensa Bioscience Comparables
Compare Infensa Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neurexis Therapeutics | 80% | |
| Forcefield Therapeutics | 79% | |
| NoNO Inc. | 78% | |
Infensa Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 7, 2024 | ||||
| Series A | Jul 4, 2022 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 1811% from 47 to 898.
- Oct 7, 2024
$12.1M grant received from health-gov.
Infensa Bioscience Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Infensa Bioscience's valuation, stock price, and market status.